FSA
TEVA icon

Financial Sense Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Financial Sense Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.53M Sell
163,086
-2,150
-1% -$71.6K 1.09% 22
2026
Q1 		$4.98M Sell
165,236
-586,347
-78% -$18.9M 1.01% 32
2025
Q4 		$23.5M Sell
751,583
-51,521
-6% -$1.27M 4.29% 5
2025
Q3 		$16.2M Buy
803,104
+130,075
+19% +$2.28M 2.77% 12
2025
Q2 		$11.3M Buy
673,029
+267,608
+66% +$4.32M 2.66% 9
2025
Q1 		$6.23M Buy
405,421
+157,421
+63% +$2.81M 1.74% 14
2024
Q4 		$5.47M Sell
248,000
-500
-0.2% -$9.1K 1.81% 8
2024
Q3 		$4.48M Buy
248,500
+4,000
+2% +$70K 1.22% 20
2024
Q2 		$3.97M Sell
244,500
-22,810
-9% -$351K 1.21% 18
2024
Q1 		$3.77M Buy
267,310
+17,310
+7% +$218K 1.25% 20
2023
Q4 		$2.61M Buy
250,000
+1,400
+0.6% +$13.1K 0.97% 29
2023
Q3 		$2.54M Hold
248,600
– – 1.08% 26
2023
Q2 		$1.87M Sell
248,600
-3,500
-1% -$28.4K 0.79% 41
2023
Q1 		$2.23M Sell
252,100
-4,000
-2% -$39.6K 0.99% 34
2022
Q4 		$2.34M Sell
256,100
-50,200
-16% -$438K 0.96% 27
2022
Q3 		$2.47M Buy
306,300
+49,000
+19% +$433K 1.04% 17
2022
Q2 		$1.94M Buy
+257,300
New +$2.24M 0.71% 34
2022
Q1 		– Sell
-207,500
Closed -$1.66M – 141
2021
Q4 		$1.66M Sell
207,500
-51,700
-20% -$467K 0.57% 39
2021
Q3 		$2.52M Sell
259,200
-1,965
-0.8% -$18.4K 0.85% 24
2021
Q2 		$2.59M Buy
261,165
+51,565
+25% +$546K 0.81% 26
2021
Q1 		$2.42M Buy
209,600
+11,000
+6% +$126K 0.81% 29
2020
Q4 		$1.92M Sell
198,600
-3,200
-2% -$30.7K 0.69% 32
2020
Q3 		$1.82M Sell
201,800
-48,943
-20% -$518K 0.72% 29
2020
Q2 		$3.09M Sell
250,743
-3,507
-1% -$39.7K 1.1% 20
2020
Q1 		$2.28M Buy
254,250
+49,450
+24% +$507K 1.03% 22
2019
Q4 		$2.01M Buy
204,800
+68,800
+51% +$614K 0.74% 29
2019
Q3 		$936K Sell
136,000
-8,500
-6% -$65.1K 0.45% 32
2019
Q2 		$1.33M Sell
144,500
-4,050
-3% -$48.8K 0.59% 26
2019
Q1 		$2.33M Buy
148,550
+38,050
+34% +$671K 1.03% 19
2018
Q4 		$1.7M Buy
110,500
+8,275
+8% +$170K 1.08% 13
2018
Q3 		$2.2M Buy
102,225
+5,250
+5% +$122K 0.93% 20
2018
Q2 		$2.36M Buy
96,975
+24,235
+33% +$494K 1.64% 15
2018
Q1 		$1.24M Buy
72,740
+31,840
+78% +$622K 0.6% 29
2017
Q4 		$775K Buy
+40,900
New +$615K 0.36% 36
2017
Q3 		– Sell
-6,009
Closed -$200K – 101
2017
Q2 		$200K Buy
+6,009
New +$186K 0.1% 87

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Financial Sense Advisors's TEVA Position: Q2 2026 in Review

Financial Sense Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 1.3% in Q2 2026, selling an estimated $71.6K and leaving 163,086 shares worth $5.53M. The position accounts for 1.09% of the portfolio, ranked #22.

Financial Sense Advisors first reported a position in TEVA in Q2 2017 and has held it in 35 quarters since. The position peaked at $23.5M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Financial Sense Advisors held 163,086 shares of Teva Pharmaceuticals worth $5.53M as of Q2 2026.
  • Financial Sense Advisors sold 2,150 Teva Pharmaceuticals shares in Q2 2026, an estimated $71.6K.
  • Teva Pharmaceuticals made up 1.09% of Financial Sense Advisors's portfolio in Q2 2026, its #22 holding.
  • Financial Sense Advisors first reported a position in Teva Pharmaceuticals in Q2 2017 and has held it in 35 quarters since.
  • Financial Sense Advisors's Teva Pharmaceuticals position peaked at $23.5M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Financial Sense Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.